BRIEF published on 12/12/2024 at 21:35, 1 year 3 months ago Medincell Joins Euronext SBF 120 Index Market Capitalization Medincell CAC 40 Euronext SBF 120 Financial Visibility
PRESS RELEASE published on 12/12/2024 at 21:30, 1 year 3 months ago Inside Information / Other news releases Medincell joins Euronext SBF 120 & CAC Mid 60 indices, enhancing visibility and investor appeal. Market capitalization-based indices by Euronext. Effective inclusion from Dec 20 Market Capitalization Medincell Index Inclusion Euronext SBF 120 CAC Mid 60
BRIEF published on 11/28/2024 at 18:45, 1 year 3 months ago Medincell Announces Video Conference for Half-Year Results Half-year Results Schizophrenia Medincell Videoconference BEPO Technology
BRIEF published on 11/22/2024 at 18:05, 1 year 3 months ago MedinCell: Update of share capital and voting rights Share Capital Voting Rights Euronext Actions Medincell
BRIEF published on 11/06/2024 at 13:47, 1 year 4 months ago Medincell: 2024 revenues on the rise and significant clinical progress Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 1 year 4 months ago Inside Information / Other news releases Medincell achieves 25% increase in 2024 UZEDY® revenue outlook reaching $100M and key milestone in Olanzapine LAI Phase 3 clinical trials. Teva Pharmaceuticals shares Q3 results Revenue Clinical Trials Medincell Teva Pharmaceuticals UZEDY
BRIEF published on 10/01/2024 at 15:47, 1 year 5 months ago Threshold crossing by Mirova in MEDINCELL Capital Actions Threshold Crossing Medincell Mirova
BRIEF published on 09/24/2024 at 11:54, 1 year 5 months ago Teva and Medincell Present Promising Results on Olanzapine LAI for Schizophrenia Clinical Trial Schizophrenia Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/24/2024 at 11:53, 1 year 5 months ago Inside Information / Other news releases Teva and Medincell reveal positive efficacy, safety, and tolerability data from Phase 3 study on Olanzapine LAI for schizophrenia treatment, presenting at ECNP 2024 Schizophrenia Treatment Phase 3 Study Medincell Teva Olanzapine LAI
BRIEF published on 09/18/2024 at 10:13, 1 year 5 months ago Mirova crosses the threshold of 5% of voting rights in MEDINCELL Voting Rights Actions Threshold Crossing Medincell Mirova
Published on 03/17/2026 at 23:10, 26 minutes ago Redwood AI CEO Louis Dron Featured on Conversations That Matter to Discuss AI Chemistry Platform and Broader Applications
Published on 03/17/2026 at 22:30, 1 hour 6 minutes ago Galway Metals Appoints Red Cloud Financial Services to Provide Financial Advisory and Promotional Services
Published on 03/17/2026 at 21:30, 2 hours 6 minutes ago Rainy Mountain Announces Appointment of Colton Griffith to Board of Directors
Published on 03/17/2026 at 13:30, 10 hours 6 minutes ago Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 21:21, 2 hours 15 minutes ago KION GROUP AG successfully places a bond of € 500 million
Published on 03/17/2026 at 20:55, 2 hours 41 minutes ago EQS-Adhoc: thyssenkrupp nucera lowers its sales and EBIT outlook for the Group and the gH2 segment for FY 2025/26 due to higher project costs
Published on 03/17/2026 at 17:58, 5 hours 38 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 07:00, 16 hours 36 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 5 hours ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 5 hours ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 5 hours ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
